Skip to content

Development of CLL-1 chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

Development of CLL-1 chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500100811
Enrollment
Unknown
Registered
2025-04-15
Start date
2025-03-07
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myeloid leukemia (AML)

Interventions

Observation group:None

Sponsors

Henan Provincial People's Hospita,medical
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Male or female patients aged 18-70 years old; 2.Initial diagnosis of acute myeloid leukemia (AML); 3.CLL-1 positive; 4.Blood can be taken intravenously and there are no contraindications to venous blood collection; 5.Patients or their legal guardians voluntarily participate and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with a first diagnosis of APL; 2.AML patients who have received chemotherapy; 3.Those with abnormal vital signs and those who are unable to cooperate with the examination.

Design outcomes

Primary

MeasureTime frame
Raise/lower;

Secondary

MeasureTime frame
Raise/lower;Raise/lower;

Countries

China

Contacts

Public ContactWenyi Lu

Henan Provincial People's Hospita,medical

luwenyi0323@163.com+86 371 65580798

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026